Deep vein thrombosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "==Ongoing Research== '''Phase 3 Trials''' Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Mye..." |
|||
| Line 2: | Line 2: | ||
'''Phase 3 Trials''' | '''Phase 3 Trials''' | ||
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer | |||
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer<ref>http://clinicaltrials.gov/ct2/show/NCT00633893<ref/> | |||
* Primary Outcome Measures: Venous Thromboembolic Recurrence or Death | * Primary Outcome Measures: Venous Thromboembolic Recurrence or Death | ||
* Secondary Outcome Measures: Bleeding | * Secondary Outcome Measures: Bleeding | ||
Revision as of 01:30, 20 June 2012
Ongoing Research
Phase 3 Trials
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism: Sponsored by Bristol-Myers Squibb and Pfizer<ref>http://clinicaltrials.gov/ct2/show/NCT00633893The opening <ref> tag is malformed or has a bad name
- Primary Outcome Measures: Venous Thromboembolic Recurrence or Death
- Secondary Outcome Measures: Bleeding
- Estimated Enrollment: 2,430 patients
- Study Start Date: May 2008
- Estimated Study Completion Date: August 2012